Cite
HARVARD Citation
Wang, H. et al. (2019). Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer. Future oncology. pp. 181-191. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Wang, H. et al. (2019). Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer. Future oncology. pp. 181-191. [Online].